BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cowan K, Gao X, Parab V, Nguy T, Wu L, Arron JR, Townsend M, Wallin J, Cheu M, Morimoto A, Wakshull E. Fit-for-purpose biomarker immunoassay qualification and validation: three case studies. Bioanalysis 2016;8:2329-40. [PMID: 27712082 DOI: 10.4155/bio-2016-0184] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Tu J, Bennett P. Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons. Bioanalysis 2017;9:1107-22. [DOI: 10.4155/bio-2017-0084] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
2 Zhao Y, Gu H, Postelnek J, DeMichele M, Yuan L, Zhang YJ, Zeng J. Fit-for-purpose protein biomarker assay validation strategies using hybrid immunocapture-liquid chromatography-tandem-mass spectrometry platform: Quantitative analysis of total soluble cluster of differentiation 73. Anal Chim Acta 2020;1126:144-53. [PMID: 32736718 DOI: 10.1016/j.aca.2020.06.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Weller MG. Ten Basic Rules of Antibody Validation. Anal Chem Insights 2018;13:1177390118757462. [PMID: 29467569 DOI: 10.1177/1177390118757462] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
4 Gupta S, Richards S, Amaravadi L, Piccoli S, Desilva B, Pillutla R, Stevenson L, Mehta D, Carrasco-triguero M, Neely R, Partridge M, Staack RF, Zhao X, Gorovits B, Kolaitis G, Sumner G, Stubenrauch K, Zou L, Amur S, Beaver C, Berger I, Berisha F, Birnboeck H, Bower J, Cho S(, Cludts I, Cocea L, Donato LD, Fischer S, Fraser S, Garofolo F, Haidar S, Haulenbeek J, Hottenstein C, Hu J, Ishii-watabe A, Islam R, Jani D, Kadavil J, Kamerud J, Kramer D, Kurki P, Macmannis S, Mcnally J, Mullan A, Papadimitriou A, Pedras-vasconcelos J, Ray S, Safavi A, Saito Y, Savoie N, Fjording MS, Scheibner K, Smeraglia J, Song A, Stouffer B, Tampal N, der Strate BV, Verch T, Welink J, Xu Y, Yang T, Yengi L, Zeng J, Zhang Y, Zhang Y, Zoog S. 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 – LBA: immunogenicity, biomarkers and PK assays). Bioanalysis 2017;9:1967-96. [DOI: 10.4155/bio-2017-4974] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
5 Keller S, Purushothama S. Biomarker assays: is it time for a standalone regulatory guidance? Bioanalysis 2018;10:1893-5. [DOI: 10.4155/bio-2018-0279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Meyer JT, Sparling BA, Mccarty WJ, Zhang M, Soto M, Schneider S, Chen H, Roberts J, Tan H, Kornecook T, Andrews PS, Knutson CG. Pharmacological Assessment of Sepiapterin Reductase Inhibition on Tactile Response in the Rat. J Pharmacol Exp Ther 2019;371:476-86. [DOI: 10.1124/jpet.119.257105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Arnold ME, Neubert H, Stevenson LF, Garofolo F. The breadth of biomarkers and their assays. Bioanalysis 2016;8:2283-5. [PMID: 27737565 DOI: 10.4155/bio-2016-4990] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]